Intellia Therapeutics Stock In The News
NTLA Stock | USD 21.17 0.36 1.67% |
The overall news coverage of Intellia Therapeutics from major news outlets shows bullish sentiment on 25 news articles, blog posts, and TV commentaries analyzed in the last few months. Our overall analysis of Intellia Therapeutics' news coverage and content from conventional and social sources shows investors' bearish mood towards Intellia Therapeutics. The specific impact of Intellia Therapeutics news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Intellia Therapeutics' overall financial health and prospects. It also depends on the type and quality of a news publisher.
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Intellia Therapeutics headlines in addition to utilizing other, more conventional financial analysis modules. Check out Intellia Therapeutics Backtesting and Intellia Therapeutics Hype Analysis. For information on how to trade Intellia Stock refer to our How to Trade Intellia Stock guide.
Intellia |
Intellia Therapeutics Today Top News and Investor Outlook
Intellia Therapeutics Past News Timeline
Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Intellia and other traded companies coverage. We help investors stay connected with Intellia headlines for the 25th of April to make an informed investment decision based on correlating the impacts of news items on Intellia Stock performance. Please note that trading solely based on the Intellia Therapeutics hype is not for everyone as timely availability and quick action are needed to avoid losses.Intellia Therapeutics stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Intellia earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about Intellia Therapeutics that are available to investors today. That information is available publicly through Intellia media outlets and privately through word of mouth or via Intellia internal channels. However, regardless of the origin, that massive amount of Intellia data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Intellia Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Intellia Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Intellia Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Intellia Therapeutics alpha.
Intellia Largest EPS Surprises
Earnings surprises can significantly impact Intellia Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
---|---|---|---|---|---|---|---|
2017-10-31 | 2017-09-30 | -0.5 | -0.44 | 0.06 | 12 | ||
2018-05-01 | 2018-03-31 | -0.58 | -0.51 | 0.07 | 12 | ||
2020-08-06 | 2020-06-30 | -0.69 | -0.61 | 0.08 | 11 | ||
2021-02-25 | 2020-12-31 | -0.6 | -0.69 | -0.09 | 15 | ||
2017-03-14 | 2016-12-31 | -0.22 | -0.31 | -0.09 | 40 | ||
2019-05-02 | 2019-03-31 | -0.59 | -0.49 | 0.1 | 16 |
Intellia Therapeutics Stock Latest Headlines
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Intellia Therapeutics Stock. The global stock market is bearish. About 60% of major world exchanges and indexes are down. See today's market update for more information.19th of April 2024
First Week of June 21st Options Trading For Intellia Therapeutics - Nasdaq at news.google.com
9th of April 2024
Bull Market and Beyond 3 Stocks Just Waiting to Soar at fool.com
1st of April 2024
Intellia Therapeutics investors are sitting on a loss of 66 percent if they invested three... at simplywall.st
28th of March 2024
Smart Money Is Betting Big In NTLA Options at benzinga.com
21st of March 2024
Hot Stocks The 3 Best Opportunities for Investing in Biotech at investorplace.com
18th of March 2024
Intellia begins phase 3 trial for CRISPR therapy NTLA-2001 at investing.com
4th of March 2024
Disposition of 605 shares by Clark Eliana of Intellia Therapeutics at 32.99 subject to Rul... at MacroaxisInsider
15th of February 2024
Exact Sciences to Post Q4 Earnings Whats in Store at finance.yahoo.com
Intellia Therapeutics Investors Sentiment
The influence of Intellia Therapeutics' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Intellia. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Intellia Therapeutics' public news can be used to forecast risks associated with an investment in Intellia. The trend in average sentiment can be used to explain how an investor holding Intellia can time the market purely based on public headlines and social activities around Intellia Therapeutics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Intellia Therapeutics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Intellia Therapeutics' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Intellia Therapeutics' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Intellia Therapeutics.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Intellia Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Intellia Therapeutics' short interest history, or implied volatility extrapolated from Intellia Therapeutics options trading.
Check out Intellia Therapeutics Backtesting and Intellia Therapeutics Hype Analysis. For information on how to trade Intellia Stock refer to our How to Trade Intellia Stock guide.You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Complementary Tools for Intellia Stock analysis
When running Intellia Therapeutics' price analysis, check to measure Intellia Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Intellia Therapeutics is operating at the current time. Most of Intellia Therapeutics' value examination focuses on studying past and present price action to predict the probability of Intellia Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Intellia Therapeutics' price. Additionally, you may evaluate how the addition of Intellia Therapeutics to your portfolios can decrease your overall portfolio volatility.
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities |
Is Intellia Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Intellia Therapeutics. If investors know Intellia will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Intellia Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.42) | Revenue Per Share 0.409 | Quarterly Revenue Growth (0.1) | Return On Assets (0.23) | Return On Equity (0.42) |
The market value of Intellia Therapeutics is measured differently than its book value, which is the value of Intellia that is recorded on the company's balance sheet. Investors also form their own opinion of Intellia Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Intellia Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Intellia Therapeutics' market value can be influenced by many factors that don't directly affect Intellia Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Intellia Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Intellia Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Intellia Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.